Category Archives: News
Neoadjuvant Chemotherapy vs. Primary Surgery for Advanced Ovarian Cancer
Neoadjuvant chemotherapy followed by interval debulking was not inferior to the standard therapy of primary surgery followed by chemotherapy. Standard therapy for advanced ovarian cancer consists of primary debulking surgery followed by chemotherapy. But some patients present with clinical features … Continue reading
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
ABSTRACT Context Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. Objective To estimate risk and mortality reduction stratified by mutation and prior cancer status. Design, Setting, … Continue reading
Health Law Requires Continued Coverage For Patients In Clinical Trials
When Richard Crusoe was diagnosed with a rare form of soft tissue cancer called liposarcoma, the retired firefighter and his family pinned their hopes of slowing the cancer’s advance on a drug that was being tested in a clinical trial. … Continue reading
More painkillers needed for cancer patients-experts
Cancer patients, particularly in developing regions, are in dire need of painkillers and affordable drugs, experts said. “It’s shocking and shameful the number of people who suffer needlessly because of the lack of access to analgesics,” John Seffrin, chief executive … Continue reading
Avenue opens for new ovarian cancer drugs
New drugs could be developed to hit ovarian cancer with a double blast, scientists have said after identifying a key protein in ‘runaway’ cell division. At present the chemotherapy drug paclitaxel, also known by its brand names Paxol and Abraxane, … Continue reading
Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival.
Purpose: To compare accuracy and interobserver variability in the detection and localization of recurrent ovarian cancer with contrast material-enhanced (CE) computed tomography (CT) and positron emission tomography (PET)/CT and determine whether imaging findings can be used to predict survival. Materials … Continue reading
Report: Cancer Is The World’s Costliest Disease
Cancer is the world’s top “economic killer” as well as its likely leading cause of death, the American Cancer Society contends in a new report it will present at a global cancer conference in China this week. Cancer costs more … Continue reading
Ovarian Cancer National Alliance and Susan G. Komen for the Cure® Appeal to FDA and Key Lawmakers on Avastin Issue
Washington D.C. – August 12, 2010. The Ovarian Cancer National Alliance (OCNA) and Susan G. Komen for the Cure® today urged the U.S. Food and Drug Administration to continue to allow the use of the drug bevacizumab, commonly known as … Continue reading
Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival
Purpose: To compare accuracy and interobserver variability in the detection and localization of recurrent ovarian cancer with contrast material–enhanced (CE) computed tomography (CT) and positron emission tomography (PET)/CT and determine whether imaging findings can be used to predict survival. Materials … Continue reading
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. Two of these rings (subunits A and B) provide the framework for covalent interaction with the minor … Continue reading
DNA Dilemma: The Full Interview With the FDA on DTC Genetic Tests (Newsweek)
In an interview yesterday, the FDA made some potentially controversial and confusing statements about consumer genetics, an area it’s in the process of deciding how to regulate. I criticize the agency in my piece for not being fully transparent, so … Continue reading
